| SC 13G/A | 2017-10-27 | AbbVie Inc. | ENANTA PHARMACEUTICALS INC | 924,662 | 4.8% | EDGAR |
| SC 13D | 2017-10-06 | AbbVie Inc. | EXICURE, INC. | 1,939,113 | 5.5% | EDGAR |
| SC 13G/A | 2017-08-11 | AbbVie Inc. | REATA PHARMACEUTICALS INC | 720,937 | 4.9% | EDGAR |
| SC 13G/A | 2017-05-01 | AbbVie Inc. | REATA PHARMACEUTICALS INC | 1,190,473 | 8.6% | EDGAR |
| SC 13G/A | 2017-02-13 | Capital Research Global Investors | AbbVie Inc. | 174,963,752 | 10.7% | EDGAR |
| SC 13G/A | 2017-02-09 | VANGUARD GROUP INC | AbbVie Inc. | 109,536,763 | 6.7% | EDGAR |
| SC 13G/A | 2017-01-19 | BlackRock Inc. | AbbVie Inc. | 92,418,567 | 5.7% | EDGAR |
| SC 13G | 2016-11-10 | Capital Research Global Investors | AbbVie Inc. | 164,407,574 | 10.0% | EDGAR |
| SC 13G | 2016-06-06 | AbbVie Inc. | REATA PHARMACEUTICALS INC | 1,640,473 | 17.9% | EDGAR |
| SC 13G/A | 2016-02-16 | Capital Research Global Investors | AbbVie Inc. | 77,568,659 | 4.7% | EDGAR |
| SC 13G/A | 2016-02-10 | BlackRock Inc. | AbbVie Inc. | 99,591,579 | 6.1% | EDGAR |
| SC 13G/A | 2016-02-10 | VANGUARD GROUP INC | AbbVie Inc. | 99,619,621 | 6.1% | EDGAR |
| SC 13G/A | 2015-02-13 | Capital Research Global Investors | AbbVie Inc. | 100,552,589 | 6.3% | EDGAR |
| SC 13G/A | 2015-02-10 | VANGUARD GROUP INC | AbbVie Inc. | 88,843,397 | 5.6% | EDGAR |
| SC 13G/A | 2015-02-09 | BlackRock Inc. | AbbVie Inc. | 114,453,015 | 7.2% | EDGAR |
| SC 13G | 2014-02-13 | Capital Research Global Investors | AbbVie Inc. | 99,962,125 | 6.3% | EDGAR |
| SC 13G | 2014-02-10 | VANGUARD GROUP INC | AbbVie Inc. | 82,276,225 | 5.2% | EDGAR |
| SC 13G | 2014-02-07 | AbbVie Inc. | ENANTA PHARMACEUTICALS INC | 1,072,103 | 6.0% | EDGAR |
| SC 13G | 2014-01-28 | BlackRock Inc. | AbbVie Inc. | 105,532,577 | 6.6% | EDGAR |